- Home
- ICCM vs GNTA Comparison
ICCM vs GNTA Comparison
Compare ICCM & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCM
- GNTA
- Stock Information
- Founded
- ICCM 2006
- GNTA 2014
- Country
- ICCM Israel
- GNTA Italy
- Employees
- ICCM N/A
- GNTA N/A
- Industry
- ICCM
- GNTA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ICCM
- GNTA Health Care
- Exchange
- ICCM Nasdaq
- GNTA Nasdaq
- Market Cap
- ICCM 61.1M
- GNTA 59.7M
- IPO Year
- ICCM N/A
- GNTA 2021
- Fundamental
- Price
- ICCM $0.98
- GNTA $3.23
- Analyst Decision
- ICCM Strong Buy
- GNTA
- Analyst Count
- ICCM 1
- GNTA 0
- Target Price
- ICCM $2.50
- GNTA N/A
- AVG Volume (30 Days)
- ICCM 2.5M
- GNTA 14.3K
- Earning Date
- ICCM 11-25-2025
- GNTA 01-01-0001
- Dividend Yield
- ICCM N/A
- GNTA N/A
- EPS Growth
- ICCM N/A
- GNTA N/A
- EPS
- ICCM N/A
- GNTA N/A
- Revenue
- ICCM $2,787,000.00
- GNTA N/A
- Revenue This Year
- ICCM $3.95
- GNTA N/A
- Revenue Next Year
- ICCM $266.15
- GNTA N/A
- P/E Ratio
- ICCM N/A
- GNTA N/A
- Revenue Growth
- ICCM N/A
- GNTA N/A
- 52 Week Low
- ICCM $0.48
- GNTA $2.56
- 52 Week High
- ICCM $1.66
- GNTA $7.28
- Technical
- Relative Strength Index (RSI)
- ICCM 46.89
- GNTA 49.34
- Support Level
- ICCM $0.93
- GNTA $2.99
- Resistance Level
- ICCM $1.40
- GNTA $3.22
- Average True Range (ATR)
- ICCM 0.07
- GNTA 0.22
- MACD
- ICCM -0.01
- GNTA 0.04
- Stochastic Oscillator
- ICCM 12.45
- GNTA 71.48
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.